The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
Open accessAbstract
Key Points: Pomalidomide plus low-dose dexamethasone significantly improved PFS vs pomalidomide alone in relapsed and refractory multiple myeloma. Pomalidomide plus low-dose dexamethasone is an important new treatment option for RRMM patients who have received multiple prior therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Data from a number of in vitro studies support the hypothesis that thalidomide analogues synergize with dexamethasone49,50, proteasome inhibitors51,52, histone deacetylase inhibitors53,54 and a variety of other agents”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Self-citationBladé, J., Samson, D., Reece, D. E., Apperley, J. F., Björkstrand, B., Gahrton, G., Gertz, M. A., Giralt, S. A., Jagannath, S., & Vesole, D. H. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,516
Self-citationLenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citationLenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Self-citationHideshima, T., Chauhan, D., Shima, Y., Raje, N. S., Davies, F. E., Tai, Y., Treon, S. P., Lin, B. K., Schlossman, R. L., Richardson, P. G. G., et al. (2000) · Blood · doi:10.1182/blood.v96.9.2943 · Cited by 874
Self-citationPrevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
Palumbo, A. P., Rajkumar, S. V., Dimopoulos, M. A., Richardson, P. G. G., Miguel, J. F. S., Barlogie, B., Harousseau, J., Zonder, J. A., Cavo, M., Zangari, M., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2405062 · Cited by 840
Self-citationMiguel, J. F. S., Weisel, K. C., Moreau, P., Lacy, M. Q., Song, K., Delforge, M., Karlin, L., Goldschmidt, H., Banos, A., Oriol, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70380-2 · Cited by 806
Self-citationCorral, L. G., Haslett, P. A. J., Muller, G. W., Chen, R., Wong, L.-M., Ocampo, C. J., Patterson, R. T., Stirling, D., & Kaplan, G. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.1.380 · Cited by 792
Corral, L. G., Haslett, P. A. J., Muller, G. W., Chen, R., Wong, L. M., Ocampo, C. J., Patterson, R. T., Stirling, D., & Kaplan, G. (1999) · PubMed · Cited by 729
Kumar, S. K., Lee, J. H., Lahuerta, J. J., Morgan, G., Richardson, P. G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., et al. (2012) · Leukemia · doi:10.1038/leu.2011.196 · Cited by 721
Self-citation
Research works printed but not linked: 1
- Rychack, 2011, Overcoming resistance; the use of pomalidomide (POM) and dexamethasone (DEX) in re-sensitizing lenalidomide (LEN)-resistant multiple myeloma (MM) cells., Haematologica, 96, S126
Cited by
Sorted by citations
Items 201–300 of 381
Nonselective proteasome inhibitors in multiple myeloma and future perspectives
Gavriatopoulou, M., Malandrakis, P., Ntanasis‐Stathopoulos, I., & Dimopoulos, M. A. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1999411 · Cited by 13
Immunomodulatory Agents and Proteasome Inhibitors in the Treatment of Multiple Myeloma
Noonan, K. A., & Colson, K. (2017) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2017.05.005 · Cited by 12
Büyükkaramikli, N., de Groot, S., Fayter, D., Wolff, R. F., Armstrong, N., Stirk, L., Worthy, G., de Almeida, F. A., Kleijnen, J., & Al, M. (2017) · PharmacoEconomics · doi:10.1007/s40273-017-0581-6 · Cited by 11
Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma
Fouquet, G., Pegourié, B., Macro, M., Petillon, M. O., Karlin, L., Caillot, D., Roussel, M., Arnulf, B., Mathiot, C., Marit, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw017 · Cited by 11
Pomalidomide Desensitization in a Patient Hypersensitive to Immunomodulating Agents
Seki, J. T., Sakurai, N., Lam, W., & Reece, D. E. (2017) · Current Oncology · doi:10.3747/co.24.3572 · Cited by 11
Current developments in the combination therapy of relapsed/refractory multiple myeloma
Maples, K. T., Joseph, N. S., & Harvey, R. D. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1828071 · Cited by 11
Moreau, P., Weisel, K. C., Song, K., Gibson, C. J., Saunders, O., Sternas, L. A., Hong, K., Zaki, M. H., & Dimopoulos, M. A. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1180685 · Cited by 11
Self-citationBahlis, N. J., Samaras, C. J., Reece, D. E., Sébag, M., Matous, J., Berdeja, J. G., Shustik, J., Schiller, G. J., Ganguly, S., Song, K., et al. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.07.014 · Cited by 10
Self-citationBispecific Antibodies in Hematologic Malignancies: Attacking the Frontline
Shastri, T., Trabolsi, A., Arumov, A., & Schatz, J. H. (2025) · BioDrugs · doi:10.1007/s40259-025-00735-z · Cited by 12
Richardson, P. G. G., Mateos, M., Vangsted, A. J., Ramasamy, K., Abildgaard, N., Ho, P. J., Quach, H., & Bahlis, N. J. (2022) · Expert Review of Proteomics · doi:10.1080/14789450.2022.2142564 · Cited by 11
Self-citationPhase II study of pomalidomide in high-risk relapsed and refractory multiple myeloma
Usmani, S. Z., Zhang, Q. H., Stratton, K., Qu, P., Yaccoby, S., Hansen, E., Steward, D., Panozzo, S. B., Petty, N. M., Hoering, A., et al. (2014) · Leukemia · doi:10.1038/leu.2014.248 · Cited by 10
Danhof, S., Schreder, M., Strifler, S., Einsele, H., & Knop, S. T. (2015) · Case Reports in Oncology · doi:10.1159/000381983 · Cited by 10
Dede, R. J., & Pruemer, J. M. (2015) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155215569555 · Cited by 10
Leleu, X. P., Terpos, E., García‐Sánz, R., Cooney, J. P., O’Gorman, P., Minařík, J., Greil, R., Williams, C. D., Gray, D., & Szabó, Z. R. (2016) · American Journal of Hematology · doi:10.1002/ajh.24416 · Cited by 10
Evidence-Based Guidelines for Preventing and Managing Side Effects of Multiple Myeloma
Bertolotti, P., Pierre, A., Rome, S., & Faiman, B. (2017) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2017.05.008 · Cited by 9
Faiman, B. M., Doss, D. S., Colson, K., Mangan, P. A., King, T., Tariman, J. D., & and Board (2017) · Clinical journal of oncology nursing · doi:10.1188/17.cjon.s5.19-36 · Cited by 14
Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma
Ray, E. L., Jagannath, S., & Palumbo, A. P. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2016.1119041 · Cited by 10
Self-citationNadeem, O., Ailawadhi, S., Khouri, J., Williams, L. S., Catamero, D., Maples, K. T., & Berdeja, J. G. (2024) · Cancers · doi:10.3390/cancers16051023 · Cited by 11
Relapsed and Refractory Multiple Myeloma
Gentili, S., & Lonial, S. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.06.008 · Cited by 9
Self-citationPomalidomide in the Management of Relapsed Multiple Myeloma
Touzeau, C., & Moreau, P. (2016) · Future Oncology · doi:10.2217/fon-2016-0184 · Cited by 9
Kumar, S., Sharma, A., Malik, P. S., Gogia, A., Pathak, N., Sahoo, R. K., Gupta, R., Prasad, C. P., & Kumar, L. (2022) · British Journal of Haematology · doi:10.1111/bjh.18200 · Cited by 9
Fu, W., Wang, Y., Zhao, H., Niu, T., Fang, B., Liao, A., Bai, H., & Lu, J. (2022) · BMC Cancer · doi:10.1186/s12885-022-09802-y · Cited by 9
Yan, J. W., & Zheng, Z. (2023) · ChemMedChem · doi:10.1002/cmdc.202200573 · Cited by 10
Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future
Diamond, B. T., Maclachlan, K. H., Chung, D. J., Lesokhin, A. M., & Landgren, O. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101140 · Cited by 9
Alam, P., Shakeel, F., Iqbal, M., Foudah, A. I., Alqarni, M. H., Aljarba, T. M., Bar, F. M. A., & Alshehri, S. (2023) · ACS Omega · doi:10.1021/acsomega.3c04382 · Cited by 9
Treatment of Relapsed/Refractory Multiple Myeloma
Neri, P. E., Bahlis, N. J., Paba‐Prada, C. E., & Richardson, P. G. G. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40320-5_10 · Cited by 10
Self-citationShould minimal residual disease negativity be the end point of myeloma therapy?
Anderson, K. C. (2017) · Blood Advances · doi:10.1182/bloodadvances.2016000117 · Cited by 9
Self-citationCurrent and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma
Podar, K., & Pecherstorfer, M. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1340942 · Cited by 9
Usami, E., Kimura, M., Takenaka, S., Iwai, M., Teramachi, H., & Yoshimura, T. (2018) · Molecular and Clinical Oncology · doi:10.3892/mco.2018.1775 · Cited by 9
Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma
Eleutherakis‐Papaiakovou, E., Gavriatopoulou, M., Ntanasis‐Stathopoulos, I., Kastritis, E., Terpos, E., & Dimopoulos, M. A. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1685879 · Cited by 9
Suzuki, K. (2020) · International Journal of Hematology · doi:10.1007/s12185-020-02841-w · Cited by 9
Varma, G., Fogel, L., Gordon, B., Saldarriaga, M. M., Ahn, J., Aleman, A., Caro, J., Rosenberg, M. C., Monge, J., Parmar, H. V., et al. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2446617 · Cited by 8
Self-citationDrugging the undruggable: Chemical and biological insights into molecular glues in the pipeline
Metwally, K. A., Yahya, G., & Abo-Dya, N. E. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118132 · Cited by 9
The renal damage and mechanisms relevant to antitumoral drugs
Tang, J., Yang, N., Pan, S., Ren, P., Chen, M., Jin, J., He, Q., & Zeng, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1331671 · Cited by 8
Self-citationHan, X., Jiang, X., He, J., Zheng, G., Xiong, Y., Wen, Y., Yang, Y., He, D., Chen, Q., Zhao, Y., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.7232 · Cited by 8
The safety of pomalidomide for the treatment of multiple myeloma
Jones, J. R., Pawlyn, C., Davies, F. E., & Morgan, G. J. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1154039 · Cited by 9
Therapeutic outcome of early-phase clinical trials in multiple myeloma: a meta-analysis
van Nieuwenhuijzen, N., Frunt, R., May, A. M., & Minnema, M. C. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00441-3 · Cited by 8
Selinexor for the treatment of patients with previously treated multiple myeloma
Mo, C. C., Jagannath, S., Chari, A., Nooka, A. K., Lonial, S., Siegel, D. S. D., Biran, N., Gasparetto, C., Bahlis, N. J., & Richardson, P. G. G. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.1923473 · Cited by 8
Self-citationA practical approach to relapsed multiple myeloma
Mikhael, J. R. (2014) · Hematology · doi:10.1182/asheducation-2014.1.262 · Cited by 8
Self-citationMultiple Myeloma and Related Disorders
Rajkumar, S. V., & Dispenzieri, A. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00101-8 · Cited by 8
The safety of current and emerging therapies for multiple myeloma
Nadeem, O., & Anderson, K. C. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1733968 · Cited by 8
Self-citationPanobinostat for the treatment of multiple myeloma
Surati, M. J., Valla, K., Shah, K. S., Panjic, E. H., & Lonial, S. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.999665 · Cited by 8
Self-citationDechow, T. N., Aldaoud, A., Behlendorf, T., Knauf, W. U., Eschenburg, H., Groschek, M., Hansen, R., Söling, U., Grebhardt, S., Siebenbach, H. U., et al. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13719 · Cited by 7
Li, Y., Wang, X., Liu, L., Zhang, C., Gomez, D., Reyes, J. F., Palmisano, M., & Zhou, S. Y. (2018) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.470 · Cited by 7
The safety of daratumumab for the treatment of multiple myeloma
Cejalvo, M. J., Ribas, P., & de la Rubia, J. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1328053 · Cited by 7
Modern Treatments and Future Directions for Relapsed/Refractory Multiple Myeloma Patients
Premkumar, V. J., Bhutani, D., & Lentzsch, S. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.06.023 · Cited by 7
Self-citationCurrent and emerging triplet combination therapies for relapsed and refractory multiple myeloma
Pantani, L., Brioli, A., Tacchetti, P., Zannetti, B. A., Mancuso, K., Rocchi, S., Martello, M., Rizzello, I., Terragna, C., Zamagni, E., et al. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2016.1127754 · Cited by 7
Practical Approaches to the Management of Dual Refractory Multiple Myeloma
Lee, H. C., Mark, T. M., & Shah, J. J. (2016) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-016-0312-7 · Cited by 6
Chen, R., Wang, Y., Luan, C., Gao, C., Zhang, X., & Chen, B. (2017) · Journal of Cancer · doi:10.7150/jca.17999 · Cited by 6
Mondal, S. A., Assaf, M. S., Liu, L., & O'Mara, E. M. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2912-7 · Cited by 6
Cicala, G., Russo, G., Santoro, V., Franchina, T., Silvestris, N., Santarpía, M., Spina, E., & Barbieri, M. A. (2024) · Pharmaceuticals · doi:10.3390/ph17101266 · Cited by 5
Li, Y., Liu, L., Lian, H., Wang, X., Hoffmann, M., Reyes, J. F., Palmisano, M., & Zhou, S. Y. (2018) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s171735 · Cited by 5
Voorhees, P. M., Suman, V. J., Efebera, Y. A., Raje, N. S., Tuchman, S. A., Valdes, C. R., Laubach, J. P., Bova‐Solem, M., Carlisle, D., Usmani, S. Z., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013623 · Cited by 6
Self-citationPrognostic indicators of lenalidomide for multiple myeloma: consensus and controversy
Kuroda, J., Kobayashi, T., & Taniwaki, M. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1044249 · Cited by 5
Sheng, Z., & Liu, G. (2015) · Hematological Oncology · doi:10.1002/hon.2192 · Cited by 5
Novel combination approaches for myeloma
Lonial, S., & Nooka, A. K. (2015) · Hematology · doi:10.1182/asheducation-2015.1.286 · Cited by 5
Self-citationSalvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?
Thumallapally, N., Yu, H., Asti, D., Vennepureddy, A., & Terjanian, T. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s110189 · Cited by 5
Neurological Complications of Chemotherapy
Vargo, C. A., Ray, L. A., & Newton, H. B. (2017) · Springer eBooks · doi:10.1007/978-3-319-57901-6_15 · Cited by 5
Guan, J., Tanaka, S., Yamada, S., Sato, I., & Kawakami, K. (2020) · Japanese Journal of Pharmacoepidemiology/Yakuzai ekigaku · doi:10.3820/jjpe.25.e2 · Cited by 5
Terpos, E., Repousis, P., Lalayanni, C., Hatjiharissi, E., Assimakopoulou, T., Vassilopoulos, G., Pouli, A. G., Spanoudakis, E., Michalis, E., Pangalis, G. A., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071509 · Cited by 5
Yashar, D., Spektor, T. M., Martinez, D., Ghermezi, M., Swift, R. A., Eades, B., Schwartz, G. K., Eshaghian, S., Lim, S. W., Vescio, R. A., et al. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.2005044 · Cited by 5
Raedler, L. A. (2016) · Europe PMC (PubMed Central) · Cited by 5
Faiman, B. M., Doss, D., Colson, K., Mangan, P., King, T., Tariman, J. D., & and Board (2017) · Clinical journal of oncology nursing · doi:10.1188/17.cjon.s5.3-6 · Cited by 5
Sunami, K., Matsue, K., Suzuki, K., Takezako, N., Shinagawa, A., Sakurai, S., Tamakoshi, H., Biyukov, T. N., Peluso, T., & Richardson, P. G. G. (2020) · Cancer Science · doi:10.1111/cas.14415 · Cited by 5
Self-citationPomalidomide in lenalidomide‐refractory multiple myeloma: Far from futile
Mo, C. C., & Richardson, P. G. G. (2019) · British Journal of Haematology · doi:10.1111/bjh.16214 · Cited by 5
Self-citationAn update in treatment options for multiple myeloma in nontransplant eligible patients
Broijl, A., & Sonneveld, P. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1075507 · Cited by 4
Practical guidance for new multiple myeloma treatment regimens: A nursing perspective
Epstein, M., & Morrison, C. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.01.010 · Cited by 5
Thromboprophylaxis in multiple myeloma
Thalambedu, N., & Hadidi, S. A. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2092856 · Cited by 5
Masood, A., Iqbal, Q., Ehsan, H., Davis, J. A., Hansen, D. K., & Hashmi, H. (2022) · Annals of Hematology · doi:10.1007/s00277-022-04999-1 · Cited by 4
Açar, İ. H., & Güvenç, B. (2023) · Hematology Reports · doi:10.3390/hematolrep15030048 · Cited by 4
Szabo, A. G., Thorsen, J., Iversen, K. F., Levring, M. B., Helleberg, C., Hermansen, E., Bønløkke, S. T., Nielsen, K., Teodorescu, E. M., Kurt, E., et al. (2023) · eJHaem · doi:10.1002/jha2.774 · Cited by 4
Medical Image Analysis of Multiple Myeloma Diagnosis Using CNN and KNN Based Approach
Sakthivel, M., Sudman, M. S. I., Ravishankar, K., Avinash, B., Kumar, A., & Ponnusamy, M. (2023) · International Conference on Self Sustainable Artificial Intelligence Systems (ICSSAS) · doi:10.1109/icssas57918.2023.10331744 · Cited by 4
A myeloma multiplex megközelítése Magyarországon 2016-ban
Varga, G., Mikala, G., Váróczy, L., & Illés, Á. (2016) · Orvosi Hetilap · doi:10.1556/650.2016.30341 · Cited by 5
IMiDs for myeloma induced renal impairment
Gavriatopoulou, M., Terpos, E., & Dimopoulos, M. A. (2018) · Oncotarget · doi:10.18632/oncotarget.26270 · Cited by 4
Baljević, M., Schiller, G. J., Mark, T. M., Domelen, D. R. V., & Gasparetto, C. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1649493 · Cited by 4
Past, Present, and Future of Dexamethasone in Multiple Myeloma and AL Amyloidosis
Banerjee, R. K., King, T., Faiman, B., Harding, S., Rosenberg, A. S., Sanchorawala, V., Mikhael, J. R., & Cowan, A. J. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-01713 · Cited by 3
Self-citationPomalidomide desensitization for hypersensitivity: A case report
Park, J. J., Huang, E., Monteleone, C. A., Kane, M. P., & COOPER, D. L. (2019) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155219889676 · Cited by 3
Thromboprophylaxis in multiple myeloma: a case-based review with practical guidelines
Charalampous, C. M., Shah, D., Kumar, S. K., & Chakraborty, R. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05733-9 · Cited by 3
Pooled Analysis of Pomalidomide for Treating Patients with Multiple Myeloma
Sun, J., Zhang, C., Zhou, J. F., & Yang, H. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.8.3163 · Cited by 3
Wang, C., He, Z.-M., Shi, Y.-Y., Zhang, L., Chen, Y., Chen, Z., & Yu, L. (2017) · Hematology · doi:10.1080/10245332.2016.1234186 · Cited by 4
Consenso Mexicano de Mieloma Múltiple
de la Peña-Celaya, J. A., Aguilar-Luévano, J., Alcivar-Cedeño, L. M., Álvarez-Vera, J. L., Anaya-Cuéllar, I., Añorve-Hernández, É., Arana-Luna, L. L., Arteaga-Ortíz, L., Baez-Islas, P. E., Banda-García, L. I., et al. (2020) · Gaceta Médica de México · doi:10.24875/gmm.m20000393 · Cited by 3
Wester, R., Dinmohamed, A. G., van der Holt, B., Zweegman, S., Minnema, M. C., Croockewit, S., Levin, M.-D., Libourel, E., de Waal, E., Sonneveld, P., et al. (2022) · HemaSphere · doi:10.1097/hs9.0000000000000683 · Cited by 3
Frolov, M. Y., & Shatalova, O. V. (2017) · FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology · doi:10.17749/2070-4909.2017.10.2.053-061 · Cited by 3
Neurological Complications of Targeted Therapies
Forst, D. A., & Wen, P. Y. (2017) · Springer eBooks · doi:10.1007/978-3-319-57901-6_16 · Cited by 3
Cesini, L., Siniscalchi, A., Grammatico, S., Andriani, A., Fiorini, A., Rosa, L. D., Zà, T., Rago, A., Caravita, T., & Petrucci, M. T. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13086 · Cited by 3
Mexican Consensus of Multiple Myeloma
de la Peña-Celaya, J. A., Aguilar-Luévano, J., Alcivar-Cedeño, L. M., Álvarez-Vera, J. L., Anaya-Cuéllar, I., Añorve-Hernández, É., Arana-Luna, L. L., Arteaga-Ortíz, L., Baez-Islas, P. E., Banda-García, L. I., et al. (2020) · Gaceta Médica de México · doi:10.24875/gmm.m20000392 · Cited by 4
Pomalidomide in the Treatment of Relapsed and Refractory Multiple Myeloma
Roziaková, Ĺ., Mistrík, M., & Bátorová, A. (2014) · Klinicka onkologie · doi:10.14735/amko2014318 · Cited by 3
Dunn, T. J., Dinner, S., Price, E., Coutre, S., Gotlib, J., Hao, Y., Berubé, C., Medeiros, B. C., & Liedtke, M. (2016) · British Journal of Haematology · doi:10.1111/bjh.13946 · Cited by 3
Le pomalidomide dans le myélome multiple
Fouquet, G., Macro, M., Decaux, O., Fohrer, C., Guidez, S., Demarquette, H., Grand, C. L., Prodhomme, C., Renaud, L., Bories, C., et al. (2015) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2015.04.007 · Cited by 3
Cerchione, C., Nappi, D., Perna, M. D., Zacheo, I., Migliaccio, I., Salvatore, D., Picardi, M., Pane, F., & Catalano, L. (2017) · Clinical Case Reports · doi:10.1002/ccr3.773 · Cited by 3
A xenograft model reveals that PU.1 functions as a tumor suppressor for multiple myeloma in vivo
Nishimura, N., Endo, S., Ueno, S., Ueno, N., Tatetsu, H., Hirata, S., Hata, H., Komohara, Y., Takeya, M., Mitsuya, H., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.03.124 · Cited by 3
Randall, K., Kaparou, M., Xenou, E., Paneesha, S., Kishore, B., Kanellopoulos, A., Lovell, R., Holder, K., Suhr, J., Baker, L., et al. (2017) · European Journal Of Haematology · doi:10.1111/ejh.12917 · Cited by 4
Brown, M. R. D., Farquhar-Smith, P. W., & Magee, D. J. (2021) · Cancer treatment and research · doi:10.1007/978-3-030-81526-4_5 · Cited by 3
Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma
Heimberg, L., & Knop, S. T. (2021) · Oncology Research and Treatment · doi:10.1159/000520364 · Cited by 3
Lau, B., Gabrie, S., Hobbs, P., Newman, J., Elzein, A., Sargant, N., Cowley, A., Nikolova, A. N., Flanagan, C., Burt, L., et al. (2025) · eJHaem · doi:10.1002/jha2.70074 · Cited by 2
Rola daratumumabu w leczeniu chorych na nawrotowego i opornego szpiczaka plazmocytowego
Salomon‐Perzyński, A., & Jamroziak, K. (2018) · Hematologia · doi:10.5603/hem.2017.0037 · Cited by 2
Wålinder, G., Genell, A., Juliusson, G., Svensson, R., Izarra, A., Crafoord, J., Carlson, K. E., Knut‐Bojanowska, D., Veskovski, L., Lauri, B., et al. (2022) · Cancer Reports · doi:10.1002/cnr2.1614 · Cited by 2
(2015) · Australian Prescriber · doi:10.18773/austprescr.2015.012 · Cited by 2
No needles needed: All-oral therapy options for relapsed and refractory multiple myeloma
Franz, J. K., Myrus, E., Sanchez, L. J., & Richter, J. R. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.100993 · Cited by 2
Monoclonal Antibodies in Relapsed-Refractory Multiple Myeloma
Sorgiovanni, I., Giudice, M. L. D., Galimberti, S., & Buda, G. (2025) · Pharmaceuticals · doi:10.3390/ph18020145 · Cited by 3
Metadata
- Authors
- Richardson, P. G., Siegel, D. S., Vij, R., Hofmeister, C. C., Baz, R., Jagannath, S., Chen, C., Lonial, S., Jakubowiak, A., Bahlis, N., Song, K., Belch, A., Raje, N., Shustik, C., Lentzsch, S., Lacy, M., Mikhael, J., Matous, J., Vesole, D., Chen, M., Zaki, M. H., Jacques, C., Yu, Z., & Anderson, K. C.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Hackensack University Medical Center (US)
- Washington University in St. Louis (US)
- The Ohio State University (US)
- Moffitt Cancer Center (US)
- Mount Sinai Medical Center, New York, NY;
- Princess Margaret Cancer Centre (CA)
- Emory University (US)
- University of Chicago Medical Center (US)
- University of Calgary (CA)
- Vancouver General Hospital (CA)
- University of Alberta (CA)
- Massachusetts General Hospital (US)
- Royal Victoria Hospital (CA)
- Columbia University (US)
- Mayo Clinic (US)
- Colorado Blood Cancer Institute (US)
- Celgene (United States) (US)
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2014-03-20
- Volume
- 123
- Issue
- 12
- Pages
- 1826-1832
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC3962162
- OpenAlex
- W2091773528
- Cited by
- 381
- References
- 43
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 17 · 2023: 14 · 2022: 39 · 2021: 30 · 2020: 31 · 2019: 24 · 2018: 30 · 2017: 54 · 2016: 48 · 2015: 48 · 2014: 27
- FWCI
- 41.83
- Type
- journal article
- Language
- en
- Update notices
- erratum (2014-05-15)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Blood (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Celgene
- National Cancer Institute (P50CA100707, P01CA155258, P30CA016058)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- pomalidomide, low-dose dexamethasone, relapsed/refractory multiple myeloma, progression-free survival, lenalidomide-refractory disease, bortezomib resistance, combination therapy, neutropenia, peripheral neuropathy, overall survival, overall response rate
- MeSH terms
- Bortezomib, Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Boronic Acids, Dexamethasone, Female, Humans, Immunologic Factors, Male, Middle Aged, Multiple Myeloma, Neoplasm Recurrence, Local, Neutropenia, Pyrazines, Thalidomide, Treatment Outcome, Disease-Free Survival, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
